• Price band of Rs 108 to  Rs 114 per Equity Share bearing face value of Rs 2 each (“Equity Shares”)
  • Bid/Offer Opening Date Monday, December 22, 2025 and Bid/Offer Closing Date Wednesday, December 24, 2025.
  • Minimum Bid Lot is 128 Equity Shares and in multiples of 128 Equity Shares thereafter

Mumbai: Gujarat Kidney and Super Speciality Ltd has fixed the price band of ₹ 108/- to ₹ 114/- per Equity Share of face value ₹ 2/- each for its maiden initial public offer.

The Initial Public Issue (“IPO” or “Issue”) of the Company will open on Monday, December 22, 2025, for subscription and close on Wednesday, December 24, 2025.

Investors can bid for a minimum of 128 Equity Shares and in multiples of 128 Equity Shares thereafter.

Equity shares outstanding as on date 5,68,43,250 Equity Shares of Rs 2 each.

The IPO is a fresh issue of up to 2,20,00,000 equity shares.

The company is one of the regional healthcare companies located in the central region of Gujarat and operates a chain of mid-sized multi-speciality hospitals, providing integrated healthcare services, with a focus on secondary and tertiary care.

We on a consolidated basis, operate seven (07) multispeciality hospitals and four (04) pharmacies operating within our Hospitals, Gujarat Kidney and Superspeciality Hospital (Vadodara), Gujarat Multispeciality Hospital (Godhra), Raj Palmland Hospital Private Limited (Bharuch), M/s. Surya Hospital and ICU (Borsad), Gujarat Surgical Hospital (Vadodara), Ashwini Medical Centre (Anand), Ashwini Medical Store (Anand) and Apex Multispeciality & Trauma Center (Bharuch) with a total bed capacity of 490 beds, approved bed capacity of 445 beds and operational bed capacity of 340 beds.

The company categorizes its healthcare services as secondary services (which are surgical services) and tertiary Services (which are super speciality surgical services). Its hospitals are providing integrated diagnostic services, either in-house, and pharmacies that cater to its patients. The company has strategically focussed on the relatively under penetrated healthcare market in Gujarat, India where it has a presence in four cities, which it believes has provided it an understanding of regional nuances, patient culture and the mindset of medical professionals and where there is under-penetration of quality and affordable healthcare services.

The company’s revenue from operations was Rs 40.24 crore during the year ended on March 31, 2025, and its net profit was Rs9.49 crore.

The company’s revenue from operations was Rs 15.26 crore during Three month period ended June 30, 2025 and its net profit was Rs 5.40 crore.

Nirbhay Capital Services Private Limited is the book-running lead manager; and MUFG Intime India Limited is the registrar of the offer.

The Offer is being made through the book-building process, wherein not more than 75% of the net offer is allocated to qualified institutional buyers, and not more than 15% and 10% of the net offer is assigned to non-institutional bidders and retail individual bidders respectively. 

Gujarat Kidney and Super Speciality Limited is proposing, subject to receipt of requisite approvals, market conditions and other considerations, to make an initial public offer of its Equity Shares and has filed a red herring prospectus dated December 12, 2025, with the RoC. The RHP is made available on the website of the SEBI at www.sebi.gov.in as well as on the website of the BRLM i.e. Nirbhay Capital Services Private Limited, at https://nirbhaycapital.com/wp-content/uploads/2025/12/GKSL_RHP_F.pdf the website of the NSE at www.nseindia.com and the website of the BSE at www.bseindia.com and the website of the Company at https://www.gujaratsuperspecialityhospital.com. Any potential investor should note that investment in equity shares involves a high degree of risk and for details relating to such risks, please see the section “Risk Factors” beginning on page 35 of the RHP. Potential investors should not rely on the DRHP for making any investment decision but should only rely on the information included in the RHP filed by the Company with the RoC.

The Equity Shares offered in the Issue have not been, and will not be, registered under the U.S. Securities Act and may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable state securities laws. The Equity Shares offered in the issue are being offered and sold only outside the United States in “offshore transactions” as defined in and in reliance on Regulation S under the U.S. Securities Act (“Regulation S”).